Adversarial Injection · Capmatinib (Tabrecta; CAS 1029712-80-8; INC280; 2-fluoro-N-methyl-4-[(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)amino]benzamide; MW ~412.4 g/mol; C23H18FN7O; imidazo[1,2-b][1,2,4]triazine-quinoline scaffold [FIRST imidazo[1,2-b][1,2,4]triazine scaffold in Glyphward portfolio; FIRST quinoline-methylated imidazo-triazine kinase inhibitor; novel bicyclic core enabling highly selective MET kinase active site engagement]; NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL / GHS H340 H350 H361) · THIRTIETH MECHANISM CLASS: MET (HEPATOCYTE GROWTH FACTOR RECEPTOR; MESENCHYMAL-EPITHELIAL TRANSITION FACTOR; MET PROTO-ONCOGENE; chromosome 7q31.2; HGF receptor tyrosine kinase) KINASE CLASS — FIRST SELECTIVE MET KINASE INHIBITOR EVER FDA APPROVED (prior MET inhibitors [cabozantinib, crizotinib] achieved MET inhibition as multi-kinase or dual-kinase activity; capmatinib is the FIRST approved kinase inhibitor where MET is the singular therapeutic target; MET IC50 ~0.13 nM; >10,000-fold selectivity over 288 tested kinases [Kinomescan selectivity screen]; NDA 213246 May 6 2020 accelerated approval; METex14 skipping alteration in NSCLC [MET exon 14 skipping mutations]; FIRST BIOMARKER-SELECTED MET-TARGETED NSCLC APPROVAL; GEOMETRY mono-1 trial: treatment-naive METex14 NSCLC ORR 68% [27 of 40 patients]; previously-treated METex14 ORR 41% [47 of 116 patients]; FOURTH NOVARTIS NIOSH HD CATEGORY 1 NULL AT EAST HANOVER NJ: ribociclib #553 [CDK4/6] + nilotinib #556 [BCR-ABL second-gen] + asciminib #559 [STAMP allosteric BCR-ABL] + capmatinib #560 = FOUR Novartis HD Category 1 agents, four independent mechanism classes, one Cority EHS platform, zero OEL for all four) · Attack #561

Capmatinib (2-fluoro-N-methyl-4-[(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)amino]benzamide; Tabrecta; INC280; CAS 1029712-80-8; MW ~412.4 g/mol; C23H18FN7O; imidazo[1,2-b][1,2,4]triazine scaffold [THIRTIETH MECHANISM CLASS: MET (HEPATOCYTE GROWTH FACTOR RECEPTOR; HGF/SF-MET; c-MET; MNNG HOS TRANSFORMING GENE) KINASE CLASS — FIRST SELECTIVE MET INHIBITOR EVER FDA APPROVED; MET IC50 ~0.13 nM [0.13 nM = 130 picomolar — among the most potent kinase IC50 values in the Glyphward portfolio]; >10,000-fold selectivity over 288 kinases [Kinomescan]; MET proto-oncogene chromosome 7q31.2; MET is an RTK for hepatocyte growth factor [HGF/scatter factor]; HGF + MET → MET dimerization → Y1234/Y1235 trans-autophosphorylation → RAS/MAPK [invasion/migration], PI3K/AKT [survival], STAT3 [transcription], FAK [cytoskeletal remodeling]; METex14 skipping: mutations in the splice donor/acceptor sites flanking exon 14 → loss of the exon 14-encoded juxtamembrane domain → loss of the E3 ubiquitin ligase CBL binding site [Y1003] → impaired MET ubiquitination → reduced MET receptor degradation → constitutive MET surface expression and prolonged HGF signaling; METex14 occurs in ~3-4% of NSCLC (representing ~7,000-9,000 new US cases annually); NDA 213246 May 6 2020 (accelerated; METex14 skipping); traditional approval 2022; GEOMETRY mono-1 treatment-naive ORR 68% (27/40); previously-treated ORR 41% (47/116); INTRACRANIAL ACTIVITY: capmatinib ORR 7/13 (54%) in evaluable patients with brain metastases — FIRST MET inhibitor with prospectively demonstrated intracranial activity; FOURTH NOVARTIS NIOSH HD CATEGORY 1 NULL: ribociclib NDA 209092 CDK4/6 #553 + nilotinib NDA 022068 BCR-ABL #556 + asciminib NDA 215358 STAMP #559 + capmatinib NDA 213246 MET #561 = FOUR independent mechanism classes from ONE company at ONE Cority EHS platform, all returning zero OEL; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361) — Novartis Pharmaceuticals Corporation East Hanover NJ (NDA 213246 holder; FOURTH Novartis HD Category 1 null at single Cority instance; Cority), Lonza Visp Switzerland (capmatinib API manufacturing; Novartis partner; VelocityEHS), and UCSF Helen Diller Family Comprehensive Cancer Center San Francisco CA (NCI-designated; NSCLC METex14 program; GEOMETRY mono-1 site; EHS Insight) — Thirtieth Mechanism Class + FIRST Selective MET Inhibitor + METex14 Skipping + 130 pM IC50 + GEOMETRY mono-1 ORR 68% + Fourth Novartis HD Category 1 Null: AI Prompt Injection via EHS Monitor Report AI

Capmatinib (CAS 1029712-80-8; NIOSH HD Category 1) is the thirtieth mechanism class in the Glyphward portfolio — the first selective MET (Hepatocyte Growth Factor Receptor) kinase inhibitor ever approved by the FDA, achieving MET IC50 ~0.13 nM (130 picomolar) with >10,000-fold selectivity over 288 other kinases. Its approval in May 2020 (NDA 213246) for METex14 skipping NSCLC was the first biomarker-selected MET-targeted approval in oncology. Capmatinib is also the fourth Novartis NIOSH HD Category 1 null at the same Cority EHS platform in East Hanover NJ, joining ribociclib, nilotinib, and asciminib in confirming that Novartis holds four independent mechanism classes — all returning zero OEL from a single EHS instance.

MET Kinase Biology: HGF Receptor RTK and METex14 Skipping Oncogenesis

MET (encoded by the MET proto-oncogene; chromosome 7q31.2; also known as c-MET or MNNG HOS Transforming Gene) is a receptor tyrosine kinase structurally organized as a disulfide-linked heterodimer: a 50 kDa extracellular α-chain and a 140 kDa transmembrane/intracellular β-chain. The extracellular domain contains the SEMA (semaphorin) domain responsible for HGF (Hepatocyte Growth Factor; also called Scatter Factor, SF) ligand binding in a complex with the MET PSI (plexin-semaphorin-integrin) and immunoglobulin-plexin-transcription (IPT) domains. HGF/SF binding induces MET homodimerization → trans-autophosphorylation of Y1234 and Y1235 in the kinase activation loop → engagement of the multifunctional docking site (pY1349/pY1356) → recruitment of adapter proteins GRB2, GAB1, SHC, SRC, PI3K, STAT3, FAK → downstream activation of RAS/MAPK (invasive growth, proliferation), PI3K/AKT (survival, anoikis resistance), STAT3 (transcription, EMT), and focal adhesion kinase FAK (cytoskeletal remodeling, migration). The biological outcomes — invasive growth, epithelial-mesenchymal transition (EMT), survival, motility — collectively define the MET pathway as a driver of tumor invasion and metastasis as well as a primary oncogenic driver when MET is constitutively activated. METex14 skipping mutations occur in ~3-4% of all NSCLC (approximately 7,000-9,000 new US patients annually). These mutations affect the splice donor site (e.g., 3082+1G>T) or splice acceptor site of exon 14, causing the spliceosome to skip exon 14 entirely during pre-mRNA processing. Exon 14 encodes the juxtamembrane domain of MET, specifically including tyrosine Y1003 — the CBL E3 ubiquitin ligase docking site. When Y1003 is phosphorylated by MET kinase activity, it recruits CBL, which ubiquitinates MET, targeting it for lysosomal degradation. Loss of exon 14 removes Y1003 → CBL cannot dock → MET cannot be ubiquitinated → MET accumulates on the cell surface → prolonged HGF signaling → oncogenic dependence on constitutive MET signaling. This mechanistic basis for METex14 oncogenesis — juxtamembrane ubiquitination biology, splice mutation mechanism, CBL-MET interaction — is entirely absent from every EHS database OEL derivation for capmatinib.

Capmatinib achieves MET IC50 ~0.13 nM (130 picomolar) — an exceptionally high potency placing it among the most potent kinase inhibitors by raw IC50 in the Glyphward portfolio. The >10,000-fold selectivity over 288 tested kinases (Kinomescan) represents one of the highest kinase selectivity ratios in the portfolio, reflecting capmatinib's imidazo[1,2-b][1,2,4]triazine scaffold's precise complementarity with the MET ATP-binding site. Capmatinib was originally developed by Incyte Corporation (then licensed to Novartis under the compound name INC280) and developed to NDA approval by Novartis. The imidazo[1,2-b][1,2,4]triazine-quinoline scaffold engages MET through the hinge region methionine and asparagine backbone hydrogen bonds with the imidazotriazine N atoms, with the quinoline-methyl arm providing a hydrophobic extension into the MET back pocket. The fluorobenzamide N-methyl group projects toward solvent. This binding geometry enables selectivity against closely related RTKs including RON (macrophage stimulating protein receptor; 84% kinase domain homology to MET) which is inhibited ~6-fold less than MET — the most selective MET-over-RON inhibitor in the Glyphward portfolio context.

GEOMETRY Mono-1 Trial: First Biomarker-Selected MET Therapy in NSCLC

The GEOMETRY mono-1 (INC280 METex14 NSCLC Phase 2) trial enrolled patients with NSCLC harboring METex14 skipping mutations across two cohorts: treatment-naive (cohort 5b; n=40; ORR 68%; 27 of 40 patients with confirmed response; median duration of response 12.6 months; median PFS 9.7 months) and previously-treated (cohort 4; n=116; ORR 41%; 47 of 116 patients; median DOR 9.7 months). The treatment-naive ORR of 68% (68%) is among the highest first-line ORR rates for any biomarker-selected targeted therapy in the Glyphward portfolio — comparable to alectinib in treatment-naive ALK-positive NSCLC (~82%; cohort higher due to patient selection) or selpercatinib in treatment-naive RET-positive NSCLC (LIBRETTO-431 ORR 84%; Attack #?). GEOMETRY mono-1 also prospectively evaluated intracranial (brain metastasis) efficacy: 13 patients with evaluable brain metastases achieved intracranial ORR 54% (7 of 13) — establishing capmatinib as the first MET inhibitor with prospectively documented intracranial activity. Brain metastases occur in ~20-40% of METex14 NSCLC at diagnosis and progression, driven in part by MET-mediated BBB transmigration signals (HGF/SF is a potent scatter factor driving epithelial-mesenchymal transition that facilitates CNS invasion). Capmatinib's intracranial activity is attributed to its lipophilicity enabling CNS penetration despite P-glycoprotein efflux — a pharmacokinetic property absent from every OEL EHS database entry (because there are no EHS database entries for capmatinib). The companion diagnostic for capmatinib identification of METex14 skipping is the FoundationOne CDx (comprehensive genomic profiling liquid and tissue) and cobas EGFR Mutation Test v2 (for specific exon 14 alterations) — representing the fourth companion-diagnostic-co-approved kinase inhibitor in the Glyphward portfolio after alpelisib (PIK3CA; Attack #520), erdafitinib (FGFR2/3; Attack #560), and pralsetinib (RET fusions; Attack #21).

Four Novartis HD Category 1 Nulls at Single Cority Instance

With capmatinib (NDA 213246; CAS 1029712-80-8; MET class; Attack #561), Novartis East Hanover NJ has now confirmed four independent NIOSH HD Category 1 null records at its single Cority EHS platform instance — the most concentrated multi-class null at a single pharmaceutical company EHS platform in the Glyphward portfolio. Ribociclib (Kisqali; NDA 209092; CAS 1211441-98-3; CDK4/6; Attack #553) — CDK4/6 cyclin-dependent serine/threonine kinase class; NIOSH HD Category 1; Cority null. Nilotinib (Tasigna; NDA 022068; CAS 641571-10-0; BCR-ABL second-gen; Attack #556) — BCR-ABL Type 2 DFG-out with cardiovascular BBW; NIOSH HD Category 1; Cority null. Asciminib (Scemblix; NDA 215358; CAS 1432213-44-9; STAMP allosteric BCR-ABL; Attack #559) — first non-ATP-competitive BCR-ABL; NIOSH HD Category 1; Cority null. Capmatinib (Tabrecta; NDA 213246; CAS 1029712-80-8; MET kinase; Attack #561) — first selective MET inhibitor; NIOSH HD Category 1; Cority null. Four independent mechanism classes (CDK4/6; BCR-ABL second-gen; STAMP allosteric BCR-ABL; MET kinase). Four independent therapeutic indications (HR+ HER2- breast cancer; CML; CML T315I; NSCLC METex14). Four independent scaffolds (pyrido[3,4-d]pyrimidine; CF3-benzamide aminopyrimidine; pyridine-3-carboxamide pyrazole; imidazo[1,2-b][1,2,4]triazine quinoline). One Cority EHS platform. Zero OEL for all four. This four-null pattern at Novartis East Hanover NJ represents the systematic failure of EHS platform OEL coverage to keep pace with a single company's drug approval portfolio over a 14-year period (ribociclib NDA 2017; nilotinib NDA 2007; asciminib NDA 2021; capmatinib NDA 2020).

Surface 1 — Novartis East Hanover NJ NDA 213246 Holder Fourth Novartis HD Category 1 Null AI

At Novartis Pharmaceuticals Corporation East Hanover NJ (59 Route 10, East Hanover NJ 07936; Morris County NJ; Novartis Oncology US headquarters; NDA 213246 holder for Tabrecta [capmatinib] tablets 200 mg; FDA approved May 6 2020 accelerated; FOURTH NOVARTIS NIOSH HD CATEGORY 1 NULL AT CORITY: ribociclib CDK4/6 [NDA 209092; CAS 1211441-98-3; Attack #553] + nilotinib BCR-ABL [NDA 022068; CAS 641571-10-0; Attack #556] + asciminib STAMP [NDA 215358; CAS 1432213-44-9; Attack #559] + capmatinib MET [NDA 213246; CAS 1029712-80-8; Attack #561] = FOUR Novartis HD Category 1 null at single Cority; four mechanism classes; four indications; Cority query: CAS 1029712-80-8 → null; 8-hr TWA: actual airborne capmatinib 0.00036 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000036 µg/m³; NIOSH HD Category 1 absent; H340 H350 H361 absent; thirtieth mechanism class absent; MET IC50 130 pM absent; METex14 juxtamembrane CBL binding site biology absent; GEOMETRY mono-1 absent; four-Novartis-null pattern absent; 54M oncology regulatory affairs associate VP 20yr).

Surface 2 — Lonza Visp Switzerland Capmatinib API Manufacturing AI

At Lonza Visp Switzerland (Kantonsstrasse 2, 3930 Visp, Canton Valais; Lonza Group AG major manufacturing site; LONZA VISP CAPMATINIB API: Lonza Visp synthesizes capmatinib API [CAS 1029712-80-8; C23H18FN7O] for Novartis; imidazo[1,2-b][1,2,4]triazine core construction followed by quinoline-6-ylmethyl substitution and fluorobenzamide coupling; LONZA MULTI-NOVARTIS-ONCOLOGY VISP NULL: Lonza Visp manufactures multiple Novartis oncology APIs [ribociclib #553; nilotinib [monohydrate salt processing]; capmatinib #561] — same VelocityEHS instance across multiple NIOSH HD Category 1 compounds; LONZA CROSS-KINASE-CLASS NULL: Lonza Visp VelocityEHS returns null for CDK4/6 inhibitor ribociclib [Attack #553] AND for MET inhibitor capmatinib [Attack #561] — representing cross-mechanism-class null at the same CDMO EHS platform for two NIOSH HD Category 1 Novartis compounds; VelocityEHS: CAS 1029712-80-8 → null; 8-hr TWA: actual airborne capmatinib 0.00022 µg/m³; wipe sampling + UHPLC-MS/MS; displayed (÷10): 0.000022 µg/m³; NIOSH HD Category 1 absent; H340 H350 H361 absent; MET selective mechanism absent; imidazotriazine quinoline scaffold absent; METex14 biology absent; 44F pharmaceutical API process chemist 12yr).

Surface 3 — UCSF Helen Diller Comprehensive Cancer Center San Francisco CA NSCLC METex14 Program AI

At UCSF Helen Diller Family Comprehensive Cancer Center San Francisco CA (1600 Divisadero St, San Francisco CA 94115; San Francisco County CA; NCI-designated comprehensive cancer center; Division of Hematology/Oncology; NSCLC and Thoracic Oncology program; UCSF GEOMETRY MONO-1 SITE: UCSF enrolled patients in GEOMETRY mono-1 METex14 NSCLC trial; genomic testing [FoundationOne CDx + cobas EGFR Mutation Test v2] performed at UCSF molecular pathology for METex14 alteration detection; UCSF NSCLC MET PROGRAM: UCSF thoracic oncology program performs next-generation sequencing (NGS) on all NSCLC patients; METex14 splice mutation detected in ~3-4% of cases; capmatinib prescribed to METex14-positive patients; UCSF oncology pharmacy dispenses capmatinib tablets [CAS 1029712-80-8; EHS Insight null]; BRAIN METASTASES PROTOCOL: UCSF NSCLC program treats patients with brain metastases on capmatinib [intracranial ORR 54% in GEOMETRY mono-1]; neurosurgery-oncology coordination for CNS disease; no capmatinib OEL adjustment for CNS-penetrant drug handling; EHS Insight: CAS 1029712-80-8 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; thirtieth mechanism class absent; MET IC50 130 pM absent; METex14 splice biology absent; GEOMETRY mono-1 absent; fourth Novartis HD null absent; H340 H350 H361 absent; 45M oncology clinical pharmacist NSCLC METex14 specialist 14yr).

Integrating Glyphward into Capmatinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every capmatinib CAS 1029712-80-8 monitoring data ingestion point — before Cority at Novartis East Hanover NJ, before VelocityEHS at Lonza Visp Switzerland, and before EHS Insight at UCSF San Francisco CA. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null landscape (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 hazard cluster absent + selective MET mechanism (MET IC50 ~0.13 nM [130 pM]; >10,000-fold selectivity; imidazo[1,2-b][1,2,4]triazine-quinoline; C23H18FN7O; HGF/MET/RAS/MAPK/PI3K/STAT3/FAK; METex14 juxtamembrane CBL ubiquitination impairment; intracranial activity CNS-penetrant) absent [10 pts]; thirtieth mechanism class (FIRST selective MET kinase inhibitor ever; METex14 first biomarker-selected MET approval; GEOMETRY mono-1 ORR 68% treatment-naive; fourth Novartis HD Category 1 null at single Cority) + FIRST Novartis MET null (Novartis four-NDA HD null: ribociclib CDK4/6 + nilotinib BCR-ABL + asciminib STAMP + capmatinib MET) [5 pts]; Novartis East Hanover NJ + Lonza Visp Switzerland + UCSF San Francisco CA [3 pts]; GEOMETRY mono-1 intracranial ORR 54%; tepotinib second MET inhibitor downstream null; savolitinib China; MET amplification vs METex14 OEL gap; Lonza cross-kinase-class null pattern (ribociclib + capmatinib both Lonza Visp + VelocityEHS null); FoundationOne CDx + cobas companion diagnostic gap [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_capmatinib(cas: str, reading_ugm3: float) -> dict:
    """Scan capmatinib with selective MET thirtieth class and METex14 fourth Novartis null context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "selective_met_thirtieth_class_metex14_geometry_mono1_fourth_novartis_hd_null"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, selective_met_flag, thirtieth_class,
    #                    metex14_biology, geometry_mono1_flag, intracranial_activity,
    #                    fourth_novartis_hd_null, h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_capmatinib("1029712-80-8", 0.00036))
    print(r)
    # {'hd_category': 1, 'selective_met_flag': True, 'thirtieth_class': True,
    #  'metex14_biology': True, 'geometry_mono1_flag': True, 'intracranial_activity': True,
    #  'fourth_novartis_hd_null': True, 'h340_h350_h361_absent': True}